Abstract:
Helicobacter pylori infection, a worldwide health issue, is typically treated with standard antibiotic therapies. However, these treatments often face resistance and non-compliance due to side effects. In this umbrella review, we aimed to comprehensively assess the impact of probiotics supplementation in different preparations on Helicobacter pylori standard treatment. We searched PubMed, Embase and Cochrane Central Register of Controlled Trials in the Cochrane Library from inception to June 1, 2023, to identify systematic reviews with meta-analyses that focused on eradication rates, total side effects and other outcomes of interest. The most comprehensive meta-analysis was selected for data extraction. AMSTAR 2 was used to assess quality of meta-analyses. Overall, 28 unique meta-analyses based on 534 RCTs were included. The results suggests that probiotics supplementation with pooled probiotic strains was significantly associated with improved eradication rates (RR 1.10, 95% CI 1.06-1.14) and reduced risk of total side effects (RR 0.54, 95% CI 0.42-0.70) compared with standard therapy alone. Single-strained or multi-strained preparation of probiotics supplementation showed similar results. Despite Bifidobacterium spp. showing the highest potential for eradication, the study quality was critically low for most meta-analyses, necessitating further high-quality research to explore the optimal probiotic strains or their combinations for Helicobacter pylori treatment.aq_start?>Kindly check and confirm the edit made in article title.
摘要:
幽门螺杆菌感染,一个世界性的健康问题,通常用标准抗生素治疗。然而,由于副作用,这些治疗通常面临阻力和不依从性。在这个伞式审查中,我们旨在全面评估不同制剂中补充益生菌对幽门螺杆菌标准治疗的影响.我们搜索了PubMed,从成立到2023年6月1日,Embase和Cochrane在Cochrane图书馆进行对照试验中央注册,以确定具有荟萃分析的系统评价,重点是根除率,总副作用和其他感兴趣的结果。选择最全面的荟萃分析进行数据提取。AMSTAR2用于评估荟萃分析的质量。总的来说,包括基于534个RCTs的28个独特的荟萃分析。结果表明,与单独的标准治疗相比,益生菌补充合并益生菌菌株与提高根除率(RR1.10,95%CI1.06-1.14)和降低总副作用风险(RR0.54,95%CI0.42-0.70)显着相关。益生菌补充剂的单应变或多应变制剂显示相似的结果。尽管双歧杆菌属。显示出最大的根除潜力,大多数荟萃分析的研究质量非常低,需要进一步的高质量研究,以探索用于幽门螺杆菌治疗的最佳益生菌菌株或其组合。aq_start?>请检查并确认在文章标题中进行的编辑。